gener
biolog
activ
peptid
act
complianc
defens
mechan
plant
mammal
consid
one
first
form
chemic
protect
eukaryot
cell
bacteria
protozoa
fungi
virus
develop
throughout
cours
evolut
effect
natur
peptid
studi
sinc
sinc
variou
therapeut
activ
propos
gramneg
gramposit
bacteria
mechan
peptid
action
depend
structur
enhanc
modif
nativ
peptid
chemic
synthes
counterpart
addit
screen
librari
nativ
structur
effici
peptid
select
commonli
use
phage
display
silico
approach
peptid
design
mimic
interact
conserv
surfac
protein
case
varieti
pathogen
mutagen
shift
peptid
sequenc
could
modifi
preserv
therapeut
effici
recent
year
research
explor
variou
method
improv
peptid
synthesi
technolog
solidliquid
phase
synthesi
commerci
scale
econom
biolog
prospect
well
discuss
strength
weak
opportun
threat
swot
analysi
fosgerau
good
efficaci
safe
select
predict
metabol
strength
peptid
drug
product
hand
chemic
physic
stabil
prone
hydrolysi
tendenc
aggreg
weak
peptid
pharmaceut
influenza
highli
contagi
febril
influenza
virus
caus
acut
respiratori
diseas
influenza
virus
caus
ill
signific
morbid
mortal
worldwid
consid
potenti
pandem
agent
due
high
mutat
rate
may
result
format
new
subtyp
emerg
threat
novel
pandem
influenza
strain
spread
human
popul
well
increas
resist
convent
antivir
drug
encourag
research
effort
develop
new
therapi
influenza
virus
review
present
comprehens
overview
peptid
therapeut
potenti
specif
target
influenza
virus
order
understand
therapeut
potenti
peptid
influenza
viru
necessari
understand
viral
replic
cycl
influenza
viru
figur
envelop
viru
orthomyxovirida
famili
viral
genom
compos
eight
segment
singlestrand
neg
sens
rna
creat
ribonucleoprotein
complex
rnp
polymeras
protein
pa
nucleoprotein
np
life
cycl
start
attach
viru
host
cell
via
viral
hemagglutinin
ha
hemagglutinin
trimer
surfac
glycoprotein
receptor
recogn
sialic
acid
surfac
host
cell
viru
entri
receptormedi
endocytosi
fusion
process
mediat
ha
trimer
activ
low
ph
late
endosom
ha
structur
destabil
conform
chang
consequ
nterminu
glycoprotein
expos
insert
endosom
membran
result
fusion
viral
endosom
membran
ha
molecul
previous
proteolyt
cleav
glycoprotein
abl
mediat
fusion
interior
environ
viral
particl
acidifi
ion
channel
form
protein
lead
dissoci
viral
matrix
protein
viral
ribonucleoprotein
vrnp
complex
protein
subsequ
releas
host
cell
cytoplasm
transport
nucleu
site
viral
rna
replic
transcript
replic
transcript
vrna
catalyz
cell
nucleu
viral
rna
polymeras
complex
influenza
viral
mrna
translat
host
cell
translat
machineri
newli
synthet
viral
protein
ha
neuraminidas
na
protein
transport
plasma
membran
gener
assum
influenza
envelop
deriv
host
cell
membran
includ
lipid
raft
rich
cholesterol
sphingolipid
figur
lipid
raft
serv
platform
concentr
ha
na
effect
viral
fusion
releas
host
cell
protein
play
role
assembl
process
sinc
interact
lipid
membran
protein
abund
infect
cell
regul
ph
endoplasm
reticulum
transport
vesicl
ha
synthesi
trimer
transport
plasma
membran
protein
thu
ensur
correct
fold
ha
trimer
neuraminidas
second
main
surfac
glycoprotein
need
releas
new
assembl
viron
particl
cell
surfac
protein
found
raft
peripheri
appear
mediat
membran
scission
particl
releas
infect
cell
viru
bud
process
two
mechan
inhibit
viru
entri
peptid
propos
first
case
peptid
compet
sialic
acid
sa
bind
block
receptor
site
ha
figur
step
second
mechan
involv
interfer
ha
conform
chang
necessari
viral
fusion
figur
step
ii
thu
fusion
viral
endosom
membran
block
releas
rna
host
cell
prevent
viral
replic
mechan
peptid
action
shown
figur
entri
blocker
peptid
promis
prospect
candid
viral
therapi
applic
jone
et
al
demonstr
use
amino
acid
peptid
deriv
signal
sequenc
fibroblast
growth
factor
studi
confirm
broadspectrum
activ
peptid
human
swine
avian
influenza
strain
influenza
b
virus
pretreat
mice
peptid
show
protect
influenza
viru
demonstr
decreas
viral
titer
lung
infect
anim
although
postinfect
treatment
peptid
effect
pretreat
note
peptid
effect
rimantadin
protect
mice
infect
peptid
inhibit
chicken
red
blood
cell
agglutin
valu
rang
result
confirm
abil
peptid
inhibit
viral
attach
furthermor
analysi
show
low
cytotox
peptid
madindarbi
canin
kidney
mdck
cell
rang
concentr
exceed
medium
contain
bsa
subsequ
studi
minim
optim
sequenc
rrkklavllalla
confer
antivir
activ
similar
eb
addit
newli
identifi
peptid
rrkkvallavllalla
possess
significantli
enhanc
antivir
potenti
virucid
activ
influenza
explor
nterminu
peptid
characterist
sequenc
rrkk
influenc
solubl
result
studi
show
four
amino
acid
cterminu
seven
amino
acid
nterminu
could
delet
preserv
antivir
activ
result
indic
peptid
ndfrskt
abil
interact
ha
exhibit
strong
antivir
effect
neglig
hemolyt
activ
flupep
mix
predominantli
hydrophob
peptid
capabl
interact
ha
block
viral
fusion
peptid
deriv
tkip
peptid
mimet
suppressor
cytokin
signal
protein
known
activ
modul
inflammatori
cytokin
respons
known
effect
antivir
drug
poxvirus
varieti
influenza
subtyp
inhibit
flupep
nanomolar
concentr
mdck
cell
inhibitori
peptid
identifi
use
phage
display
librari
novel
alkyl
peptid
sequenc
retriev
dock
simul
proven
peptid
mimick
sialic
acid
recogn
receptorbind
site
ha
seem
rlxrxmxxxk
motif
crucial
inhibitori
activ
homolog
highli
conserv
sequenc
within
ha
mani
influenza
strain
amino
termin
alkyl
chain
play
import
role
direct
peptid
selfassembl
micel
stabil
peptid
allow
interact
multipl
bind
partner
huttl
et
al
describ
nmodifi
peptid
palmit
acid
due
micel
structur
peptid
entropi
reduc
affin
ha
increas
comparison
unmodifi
linear
peptid
although
mechan
bind
micel
peptid
ha
remain
unclear
concept
potenti
futur
exploit
anoth
peptid
block
bind
ha
sialic
acid
flufirvitid
current
test
clinic
trial
besid
interf
viru
entri
modul
immun
system
activ
product
antiinflammatori
cytokin
chemokin
increas
activ
neutrophil
cell
improv
phagocytosi
macrophag
special
group
peptid
influenza
viru
cyclic
delta
defensin
retrocyclin
form
coupl
n
ctermin
domain
occurr
describ
primat
meanwhil
previou
studi
shown
abil
inhibit
hiv
viru
abil
bind
hiv
surfac
protein
similar
mechan
suppos
influenza
viru
anoth
class
antivir
peptid
antilipopolysaccharid
peptid
salp
salp
origin
base
lpsbind
domain
limulu
antilipopolysaccharidefactor
lalf
discov
gutsmann
colleagu
peptid
antimicrobi
activ
gramposit
gramneg
bacteria
recent
salp
show
antivir
activ
envelop
virus
hiv
hcv
hbv
investig
hoffman
cowork
report
salp
abl
inhibit
influenza
viru
replic
variou
influenza
viru
subtyp
prevent
viru
attach
host
cell
vitro
vivo
bind
nacetylneuramin
acid
major
compon
influenza
viru
receptor
viral
envelop
deriv
host
cell
membran
contain
lipid
raft
rich
sphingolipid
cholesterol
shown
figur
compound
provid
amphipath
charact
neg
charg
respons
electrostat
interact
posit
charg
cation
peptid
gener
peptidemembran
interact
mediat
electrostat
interact
membran
disrupt
accomplish
differ
mean
field
antimicrobi
peptid
mechan
action
quit
well
understood
topic
describ
detail
viral
envelop
adopt
host
cell
thu
exhibit
strong
neg
charg
bacteri
membran
may
seem
antivir
peptid
result
less
select
howev
sever
antivir
peptid
caus
viral
envelop
disrupt
report
mechan
antivir
action
virus
either
target
viral
membran
gener
lipid
raft
rich
cholesterol
latter
case
result
destabil
viral
surfac
protein
alreadi
enrich
lipid
raft
domain
common
mechan
action
summar
figur
cathelicidin
human
antivir
peptid
abl
disrupt
viral
envelop
shown
elicit
number
host
protect
mechan
promot
barrier
repair
chemokin
cytokin
product
modul
dendrit
cell
differenti
tcell
polar
well
demonstr
potent
antisepsi
antiinflammatori
properti
one
cathelicidin
name
human
produc
precursor
accumul
neutrophil
granul
may
also
produc
epitheli
cell
acut
respons
pathogen
mechan
action
relat
interact
peptid
viral
envelop
carpet
model
character
format
continu
layer
lipid
bilay
surfac
result
membran
destabil
potenc
influenza
viru
seem
similar
human
defensin
involv
direct
interact
viru
without
affect
viral
aggreg
inhibit
bind
uptak
viru
cell
may
import
contributor
initi
innat
defens
influenza
viru
lactoferrin
wide
present
variou
secretori
fluid
abl
interact
viral
envelop
also
receptor
cell
membran
host
cell
interact
viral
hemagglutinin
therefor
surpris
bovin
lactoferrin
found
possibl
agent
abil
disrupt
viru
envelop
three
sequenc
deriv
lactoferrin
skhssldcvlrp
agddqgldkcvpnskek
ngessadwakn
inhibit
influenza
viru
activ
femtomolar
concentr
improv
stabil
circul
time
balco
et
al
show
lactoferrin
could
encapsul
liposom
without
loss
activ
light
ionic
strength
ph
chang
stimuli
stimul
cargo
releas
thu
liposom
could
use
preserv
peptid
drug
tissu
transport
develop
approach
deserv
detail
attent
futur
probabl
bestknown
membran
disrupt
peptid
melittin
acid
peptid
form
major
compon
european
honeybe
api
mellifera
venom
melittin
primari
structur
gigavlkvlttglpaliswikrkrqq
exhibit
varieti
effect
lipid
bilay
membran
deform
vesicl
format
artifici
pore
disrupt
lysi
current
peptideinduc
disrupt
virion
envelop
vagu
understood
two
discuss
model
membran
disrupt
invok
explain
releas
lipid
content
bilay
form
ruptur
mostli
form
toroid
pore
character
peptid
aggreg
lipid
bilay
surfac
subsequ
perpendicular
permeat
lipid
bilay
transmembran
potenti
chang
andor
ii
lipid
bilay
destructionsolubil
carpet
mechan
mention
lu
et
al
use
realtim
quartz
crystal
microbal
trace
dynam
behavior
lipid
bilay
interact
melittin
result
show
reach
threshold
peptid
concentr
typic
carpet
model
follow
mass
remov
includ
releas
lipid
probabl
lipidmelittin
complex
leakag
vesicl
compon
disrupt
bilay
curvatur
lead
micel
releas
lipid
crucial
final
virion
destroy
transient
open
membran
enabl
passag
low
molecular
mass
molecul
prior
complet
membran
lysi
li
cowork
test
mucroporin
optim
peptid
variant
lfrlikslikrlvsafk
employ
peptid
antivir
action
measl
sarscov
influenza
virus
mucoporin
design
base
protein
sequenc
mucroporin
enhanc
net
posit
charg
hydrophil
side
replac
glycin
prolin
residu
lysin
arginin
found
virucid
activ
notabl
increas
wherea
origin
mucroporin
show
virucid
activ
influenza
strain
inhibit
model
could
explain
direct
interact
viru
envelop
therebi
decreas
infect
viru
due
fact
analogu
repres
practic
tool
develop
broadspectrum
antivir
agent
especi
rna
virus
viral
rnadepend
rna
polymeras
rdrp
one
ratelimit
enzym
influenza
viru
transcript
replic
compos
three
polymeras
subunit
pa
subunit
respons
polymer
reaction
endonucleas
cleavag
respons
recogn
bind
cap
structur
host
mrna
exact
role
pa
recent
clarifi
nterminu
pa
subunit
form
domain
endonucleas
activ
pa
endonucleas
respons
cleavag
host
premrna
rdrp
held
togeth
noncoval
interact
disrupt
rdrp
assembl
repres
remark
opportun
inhibit
enzym
function
viru
replic
figur
step
iii
reason
interact
promis
target
design
new
antiinfluenza
drug
figur
numer
author
use
peptid
order
interfer
polymeras
function
enzym
ghanem
cowork
test
kinet
viral
polymeras
subunit
interact
immunoprecipit
method
peptid
could
bind
pa
subunit
inhibit
influenza
replic
cycl
interf
viral
polymeras
activ
prefer
peptid
bind
conserv
site
influenza
pa
subunit
approach
repres
promis
tool
block
influenza
viru
strain
chase
et
al
describ
elisabas
assay
investig
peptid
capabl
impair
polymeras
complex
format
present
system
includ
factor
could
play
role
proteinprotein
interact
bind
domain
bind
kinet
stabil
trimer
format
method
enabl
test
librari
variant
small
peptid
anoth
studi
li
cowork
use
peptid
deriv
influenza
viru
strain
author
show
capabl
inhibit
viral
polymeras
activ
viral
replic
deriv
peptid
disrupt
interact
ctermin
part
correspond
ntermin
part
correspond
wunderlich
et
al
investig
peptid
deriv
pabind
domain
found
peptid
block
polymeras
activ
viral
spread
work
provid
opportun
develop
new
antivir
specif
interfer
polymeras
complex
assembl
influenza
b
virus
conti
cowork
describ
anti
influenza
effect
killer
peptid
kp
toxin
isol
yeast
proven
antimicrobi
antihuman
immunodefici
viru
type
activ
treatment
kp
demonstr
signific
inhibitori
activ
replic
two
influenza
viru
strain
evalu
hemagglutin
hemadsorpt
plaqu
assay
addit
kp
demonstr
complet
inhibit
viru
particl
product
mark
reduct
synthesi
viral
protein
kp
concentr
numer
studi
shown
group
antimicrobi
peptid
call
defensin
posit
neg
modul
infect
caus
envelop
nonenvelop
virus
defensin
play
direct
role
host
microbi
infect
innat
immun
molecul
abl
increas
activ
mucos
epithelia
inhibit
synthesi
viral
rna
protein
salvator
cowork
also
show
human
human
neutrophil
effect
inhibit
replic
influenza
viru
synthesi
viral
protein
appli
soon
infect
investig
indic
viral
inhibit
could
caus
modul
protein
kinas
c
activ
infect
cell
suggest
involv
pkc
pathway
propos
strategi
involv
peptid
deriv
influenza
matrix
protein
peptid
design
correspond
zinc
finger
region
sequenc
influenza
viru
strain
center
around
amino
acid
polymeras
inhibitori
properti
peptid
evalu
infect
induc
mice
influenza
virus
avoid
enzymat
breakdown
peptid
drug
administr
intranas
rout
well
toler
dose
mgkgday
base
suggest
result
zinc
finger
peptid
may
provid
new
class
antivir
effect
influenza
viru
influenza
spread
worldwid
yearli
season
epidem
less
frequent
pandem
pose
constant
risk
thu
need
new
antivir
drug
current
antivir
therapi
drawback
side
effect
select
resist
strain
especi
drug
resist
new
viral
strain
compel
us
devis
new
strategi
influenza
treatment
peptid
may
present
new
gener
antivir
drug
broadspectrum
activ
howev
potenti
problem
need
address
peptid
inhibitor
viral
polymeras
viral
assembl
target
intracellular
process
effect
intracellular
deliveri
peptid
still
pose
great
challeng
repeat
administr
peptid
potenti
trigger
unwant
immun
respons
mani
membran
disrupt
peptid
like
cytotox
mechan
use
disrupt
integr
viral
envelop
membran
deriv
host
cell
nevertheless
therapeut
applic
test
anim
model
yet
occur
major
peptid
studi
nonetheless
reason
ignor
profit
antivir
peptid
care
design
could
curtail
mani
abovement
problem
